Login to Your Account

More Coming in November

Celgene: Good PFS Outcome in Abraxane's Melanoma Trial

By Randy Osborne
BioWorld Today Contributing Writer

Tuesday, October 2, 2012
Investors will have to wait for November for details, but Celgene Corp. said Abraxane met its primary endpoint of progression-free survival (PFS) in a Phase III metastatic melanoma trial by the company's Swiss subsidiary.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription